Linagliptin
A DPP-4 inhibitor used to treat type 2 diabetes, and studied for its potential cardiovascular and kidney protective effects. It works by preventing the breakdown of incretin hormones that stimulate insulin secretion after meals.
Peso Molecular
472,5000 g/mol
LogP
1,90
TPSA
113,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
InChI
InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
Molecular Formula
C25H28N8O2
HBD / HBA
1 / 7
Ligações Rotacionáveis
4
Átomos Pesados
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A DPP-4 inhibitor used to treat type 2 diabetes, and studied for its potential cardiovascular and kidney protective effects. It works by preventing the breakdown of incretin hormones that stimulate insulin secretion after meals.
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Yes, Linagliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL237500. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10096344. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="linagliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/linagliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/linagliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/linagliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="linagliptin"></drugfyi-drug>